What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for it? Bryan Roberts ...

Reimbursement systems in Belgium and Europe are not prepared for cell and gene therapies Bayer’s Benelux head, Niels Hessmann ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

It was as recently as February that biotech CEOs were talking enthusiastically to Fierce about a positive “shift in the ...

So, what will the early months of 2026 look like for the biotech sector? First, let me say that the biotech sector being 'en fuego' over the past three quarters has made my year as far as my portfolio ...

State Street SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB) have delivered strong returns of 40.80% and 33.95% respectively over the trailing year, but their equal-weight versus market ...

Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and ...